11/21/2024

Janusmed kön och genus

Janusmed kön och genus – dalteparinnatrium

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Dalteparin

Dalteparin

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Fragmin (dalteparin). Summary of Product Characteristics. Swedish Medical Products Agency; 2016 [cited 2019-01-24].

  2. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354(9180):708-15.

  3. Husted SE. Targeting treatment for optimal outcome. Clin Cardiol. 2000;23 Suppl 1:I18-22.

  4. Wallentin L, Lindhagen L, Ärnström E, Husted S, Janzon M, Johnsen SP et al. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet. 2016;388(10054):1903-1911.

  5. Food and Drug Administration (FDA). Medical review - FRAGMIN (dalteparin sodium). Drugs@FDA [www]. [updated 2013-12-10, cited 2019-01-24].

  6. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-9.

  7. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-53.

  8. Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol. 1997;30(4):962-9.

  9. Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J. 1999;137:72-8.

  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2019-01-30.]

  1. Fragmin (dalteparin). Summary of Product Characteristics. Swedish Medical Products Agency; 2016 [cited 2019-01-24].
  2. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354(9180):708-15.
  3. Husted SE. Targeting treatment for optimal outcome. Clin Cardiol. 2000;23 Suppl 1:I18-22.
  4. Wallentin L, Lindhagen L, Ärnström E, Husted S, Janzon M, Johnsen SP et al. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet. 2016;388(10054):1903-1911.
  5. Food and Drug Administration (FDA). Medical review - FRAGMIN (dalteparin sodium). Drugs@FDA [www]. [updated 2013-12-10, cited 2019-01-24].
  6. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-9.
  7. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-53.
  8. Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol. 1997;30(4):962-9.
  9. Toss H, Wallentin L, Siegbahn A. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J. 1999;137:72-8.
  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2019-01-30.]